Business
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
Landmark MUSIC-DMD Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failureBOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University of Kansas Medical Center, today announced the successful treatment of the first patient i
About this update from Keen Vision Acquisition Corporation
[{"type":"image","alt":"Medera Inc.; Keen Vision Acquisition Corporation","displaySize":"","headline":null,"caption":"Medera Inc.; Keen Vision Acquisition Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/f6bc075be7aef385da5918f3e6731940"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAhTcroBLLZxs8GBi5TjvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f6bc075be7aef385da5918f3e6731940","width":300,"height":109}},"lazy":false},{"type":"text","content":"Landmark MUSIC-DMD Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failure","length":114,"tagName":"p"},{"type":"text","content":"BOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University of Kansas Medical Center, today announced the successful treatment of the first patient in the MUSIC-DMD Phase 1b clinical trial. The trial is investigating AAV1.SERCA2a, a one-time gene therapy treatment for cardiomyopathy secondary to Duchenne muscular dystrophy (DMD-CM).","length":581,"tagName":"p"},{"type":"text","content":"The patient was successfully treated via left radial artery access using Medera's proprietary minimally invasive intracoronary infusion methodology. The patient tolerated the procedure well and was discharged following an overnight hospital stay for observation.","length":266,"tagName":"p"},{"type":"text","content":""This milestone represents a pivotal advancement in the treatment of DMD-associated cardiomyopathy," said Ronald Li, PhD, CEO and co-founder of Medera. "As survival rates improve due to respiratory interventions, cardiac complications have emerged as the leading cause of mortality in DMD patients. Our Sardocor division’s innovative, first-in-human gene therapy offers a promising solution to address this critical unmet medical need through our proprietary intracoronary infusion methodology that has been shown in other indications to safely and reliably deliver the therapeutic gene directly to affected heart tissue.”","length":637,"...